Appendix VI: Reported outcomes of individual studies
YEAR | FIRST AUTHOR | JOURNAL | Angiographic success rate (%) | Clinical success rate (%) | Major bleeding complications (%) | Minor bleeding complications
(%) |
Classification bleeding complications | 30 day or in-hospital mortality | Cause of Death | Mortality 6 months (%) | Mortality 1 year (%) | Mortality 2 years (%) | Amputation during admission (%) | Specification amputation if reported | Amputation rate 6 months (%) | Amputation rate 1 year (%) |
1992 | LeBlang | J Vasc Interv Radiol | 95,5 (artery 68/72 94,4%, graft 58/60 96,7%) | 88 (artery 89, graft 87) | 4.5 | 11.4 | major: resulting in intractable pain, surgery or transfusions | 2.3 | pancreatic cancer, myocardial infarction, misc | NR | NR | NR | 8.3 | NR | NR | NR |
1992 | Buckenham | Eur J Vasc Surg | 100 | NR | 15 | NR | Major complications are: (1) an event leading to a surgical procedure that would not have been per- formed based on the patient’s initial condition; (2) haemorrhage requiring transfusion; (3) an event pro- longing hospitalisation, and (4) death | 5 | retroperitoneal hemorrhage followed by myocardial infarction | NR | NR | NR | 25 | toe amputation | NR | NR |
1991 | Goffette | Acta Radiologica | 76 | NR | 4.9 | 14 | major: shpping fibrinolysis, blood transfusion, or surgery. moderate:transient stopping of infusion or a change of infusion regimen. A minor complication did not interfere with the infusion. | 1.2 | ARDS, pulmonary embolism, vertebrobasilar embolism, multiorgan failure | NR | NR | NR | 25 | lower limb amputations | NR | NR |
1991 | Berridge | Br J Surg | 100 | 100 | 0 | 0 | major: resulting in transfusion | 15 | pneumonia, myocardial infarction | NR | NR | NR | 5 | GSA | NR | NR |
1991 | Parent | J Cardiovasc Surg (Torino) | 72,5 (artery 7/13 53,8%; graft 22/27 81,5% (prosth 17/18 94%, venous 5/9 55,6%)) | NR | 2.5 | 15 | major: requiring surgical intervention, minorL local bleeding, mild renal failure, hematuria | 2.5 | unrelated cause | NR | NR | NR | 2.5 | NR | NR | 18 |
1991 | McNamara | Circulation | 85 (artery 37/42 88%, graft 24/30 80%) | 85 | 2.8 | 4 | major: resulting in tranfusion or surgery. Minor: nothing needed examples only compression | 1.6 | systemic complication from dead leg | NR | NR | NR | 8.5 | 4 below knee, 1 transmetatarsal, 1 above knee | NR | NR |
1991 | Sullivan | Circulation | 88 | 74% | 8 | 1 | only major: an event leading to surgical therapy, which would otherwise not have been indicated, premature discontinuation of lytic infusion, prolonged hospitalization, or hemorrhage requiring transfusion | NR | NR | NR | NR | NR | 16.5 | 3 above knee, 2 below knee, 1 toe | NR | NR |
1991 | Cragg | Radiology | 70,8 (native 64,5 (low 12/17 71%, high 10/17 58,8%); grafts 82 (low 14/20 70%, high 15/18 83%)) | 76% | – | – | NR | 1.6 | cardiopulmanary complication after aspiration | NR | NR | NR | 7.9 | NR | NR | NR |
1991 | Gaston | Kans Med | 82,6% (native 11/14 78,6%; graft 8/9 88,9%) | NR | NR | NR | NR | NR | NR | NR | NR | NR | 8.7 | NR | NR | NR |
1990 | Meyerovitz | Radiology | 56,3 (uk 62,5% (10/16); rtPA 50% (8/16)) | NR | 21.8 | 6.3 | NR (rt-Pa 31, UK: 12.5) | 3 UK group | NR | NR | NR | NR | 15.6 (9.3 UK, 6.3 rt-PA) | NR | NR | NR |
1990 | Berridge | Br J Surg | NR | 83 | 0 | 13 | NR | 13 | myocardial infarction | NR | NR | NR | 3.5 | NR | NR | NR |
1989 | Earnshaw | Ann Vasc Surg | 78 | 74% | 17 | 13 | major; requiring blood tranfusio, minor;hematoma | 13 | NR | NR | NR | NR | 13 | NR | NR | NR |
1989 | Hirshberg | J Vasc Surg | NR | NR | 11.2 | 11.2 | major; requiring cessation of trombolysis and/or surgical repair | 5 | myocardial infarction, bleeding complication | NR | 4.3 | NR | NR | NR | NR | NR |
1989 | Durham | Radiology | 66% (47/71) | NR | 23 | 54 | major 23%; requiring medial or surgical intervention | 2.8 | cardiac | NR | 7.5 | NR | 11.3 | NR | NR | NR |
1989 | Sullivan | Radiology | low dose 71% (25/35) vs. high dose 83% (19/23) | NR | low dose 22.9, high dose 8.7 | NR | major: resulting in surgery, acute renal failure | NR | NR | NR | NR | NR | NR | NR | NR | NR |
1986 | Risius | Radiology | 92 (native 100% (23/23), bypass 0% (0/2) | 87 | 4 | 12 | major: resulting in surgery, minor at injection site | 5 | intracarnial hemorrhage | NR | NR | NR | 8.7 | AK, BK | NR | NR |
1988 | Earnshaw | Br J Surg | 78 | NR | 13 | 17.3 | major: requiring blood transfusion, minor: groin hematoma | 13 | stroke, pneumonia, meseteric occlusion | NR | NR | NR | 13 | NR | NR | NR |
1987 | Fiessinger | Int Angiol | 74 | 28.5 | 3 | 14 | major: requiring blood tranfusion; minor: groin hematoma, transient hematuria | 11.4 | renal failure, septcima, cerebral infraction | NR | NR | NR | 17 | NR | NR | NR |
1995 | Braithwaite | Br J Surg | 82 | NR | 22 | NR | NR | 7.4 | NR | NR | NR | NR | 13.5 | NR | NR | NR |
1995 | Braithwaite | Clin Radiol | 54 | NR | 11 | NR | NR | 21 | myocardial infarction, pulmonary embolism, malignant trombosis, oneumonie, renal failure | NR | NR | NR | 22 | NR | NR | NR |
1995 | Hicken | Can J Surg | 76 | 48 | 4 | 32 | minor: local pressure or not treated. major: requiting blood tranfusion, death, cardiorespiratory depression, pseudoaneuryms | 0 | NA | NR | NR | NR | 28 | 3 BK, 6 AK | NR | NR |
1995 | Huettl | Radiology | 69 | 69 | 18 | 29 | minor: puncture site hematoma, distal embolus; major: need for transfusion or surgery | 6.7 | NR | NR | NR | NR | 2.2 | NR | NR | NR |
1995 | Bero | J Vasc Interv Radiol | 86% (native 100% (9/9), graft 75% (prosth 2/3 67%,venous 7/9 78,8%)) | NR | 14.3 | 19 | major: requiring blood tranfusion; minor: no transfusion needed | 5 | intracranial hemorrhage | NR | NR | NR | 5 | below knee | NR | NR |
1995 | Chalmers | Cardiovasc Surg | 72,9% (native 68,8% (22/32), bypass 76% (29/38) | 75.8 | NR | NR | NR | 6.3 | multi-organ failure | NR | NR | NR | NR | NR | NR | NR |
1994 | Hye | J Vasc Surg | 92 | NR | 3.2 | 3.2 | minor: no therapy required, majr: therapy required | 0 | NR | NR | NR | NR | NR | NR | NR | NR |
1994 | Ouriel | Radiology | 75,7% (native 78% (39/49), graft 72% (prosth 88,6% (31/35)), (venous 42,1% (8/19)) | 83% | 5.8 | NR | major: required transfusion | 14.5 | cardiopulmonary complications | NR | 14 | NR | 5 | NR | NR | NR |
1994 | Varga | J Vasc Surg | 70 | NR | NR | NR | NR | NR | NR | NR | 13% | NR | NR | NR | ||
1994 | Ward | Arch Surg. | A: 75, B: 70 (native 30/41 73,2%; grafts 6/9 66,7%) | A:67%, B:48% | 20 | NR | major: required transfusion or intervention | 8.8 | NR | NR | NR | NR | 17.8 | NR | NR | NR |
1994 | STILE Investigators | Ann Surg | 81 (X/78) bypass grafts, 69 (X/170) native arteries | NR | 5.6 | NR | NR | 4.7 | NR | NR | NR | NR | 5.2 | NR | NR | NR |
1994 | Faggioli | J Vasc Surg | 53% (native 39/58 67,2%; prosth 48/76 63,2%) | 47.8% | 20.1 | NR | major: amputations, hematomas thatrequired surgical intervention or transfusion, periheral embolization pumonary edema, myocardial infacrtion, lacunar infarction, catheter trombosis | 3.7 | NR | NR | NR | NR | 8.2 | NR | NR | NR |
1993 | Bull | Acta Chir Belg | 78,9 (30/38) | NR | 21 | NR | major: death, surgical intervention required, retrombosis, distal embolization | 5.3 | multi organ failure, renal failure | NR | NR | NR | 5.3 | 5 below knee, 2 above knee | NR | I: 18, II: 24 |
1994 | Ouriel | J Vasc Surg | 70 | NR | 25 | 25 | NR | 23 | NR | NR | 51 | NR | 4 | NR | NR | NR |
1993 | Enon | Ann Vasc Surg | 100 | NR | NR | 15 local | no major/minor. Local complications | 0 | NR | NR | NR | NR | 0 | NR | NR | NR |
1993 | Kandarpa | Radiology | 20/25 80% | 64% | 16 | 56 | major: required transfusion or intervention | 8 | pneumonia, myocardial infarction | NR | NR | NR | 8 | NR | NR | NR |
1993 | Earnshaw | Br J Surg | 10/23 43% | NR | 22 | 9 | major: requiring surgery or transfusion | 17 | NR | NR | NR | NR | 17 | NR | NR | NR |
1993 | Spengel | Clin Investig | 93 | NR | 0 | 0 | 0 | NA | NR | NR | NR | 0 | NR | NR | NR | |
1993 | DeMaioribus | J Vasc Surg | 60% (native 22/36 61%; graft 28/48 58%) | NR | 10.6 | NR | major: requiring cessation of therapy, transfusion or internvention | 3 | NR | NR | NR | NR | 6 | NR | NR | NR |
1995 | Ikeda | Int Surg | 60 | NR | 40.3 | 67 | NR | NR | NR | NR | NR | NR | NR | NR | NR | 6.7 |
1996 | Ouriel | J Vasc Surg | 70,4% 95/135 | NR | major: severe or life-threathening hemorrhagic complications | 7 | NR | 10 | 13 | NR | 13 | NR | 73 | 33 | ||
1996 | Bhatnagar | J Cardiovasc Surg (Torino) | 59 (graft 45/77 58,4%; native 3/4 75%) | NR | 21 | 28.3 | NR | 4.9 | myocardial infarction, ventrical fibrillation, intracranial hemorrhage | NR | NR | NR | 5 | NR | NR | NR |
1995 | Knorring | Ann Chir Gynaecol | 59 (grafts 5/10 50%; native 40/58 69,0%) | NR | 7.7 | 12.3 | major: requiring intervention | 9 | intracerebral hemorrhage, heart failure, myocardial infarction, massive embolism | NR | NR | NR | 15 | NR | NR | 4.4 |
1996 | Hess | Eur J Vasc Endovasc Surg | 89,5% 272/304 (grafts 17/18 94%; native 255/286 89%) | NR | NR | NR | NR | 0 | NA | NR | NR | NR | 1.4 | aboven knee, below, knee, forefoot, toe | NR | NR |
1996 | Singh | Int Angiol | 15/20 75% | NR | NR | NR | NR | 17 | NR | NR | NR | NR | NR | NR | NR | NR |
1995 | McNamara | J Vasc Interv Radiol | 160/186 86% | NR | 5 | 8.5 | major: requiring intervention | 1.3 | retropritoneal bleeding, revascularisation syndrome | NR | NR | NR | 18.5 | NR | NR | NR |
1996 | Schweizer | Eur.J.Radiol. | 95/120 79,2% (UK: 44/60 73%, rt-PA: 51/60 85%) | NR | 0 | 26.5 | major:serious systemic complications | 3.9 | NR | 2.5 | NR | NR | 15.7 | NR | NR | NR |
1996 | Duda | J Vasc Interv Radiol | 89% 20 pt total UK | NR | 20 | 25 | major: requiring transfusion | 5 | myocardial infarction | NR | NR | NR | 10 | NR | NR | NR |
1996 | Braithwaite | Br J Surg | 84,1% 37/44 (high dose 17/21 81,0%; low dose 20/23 87,0%) | NR | 11.4 | 9 | major: requiring surgery, transfusion | 13.6 | NR | NR | NR | NR | 6.8 | NR | NR | NR |
1997 | Byrne | Virginia medical quarterly | 92% | 87.8% | 5.3 | NR | NR | 0 | NA | NR | NR | NR | 3.5 | NR | NR | NR |
1997 | Armon | Br J Surg | 79% 79/100 | NR | 7 | 11 | NR, tables with complications | 10 | myocardial infarction, renal failure, retroperitoneal bleeding, ischemic leg | NR | NR | NR | 9 | NR | NR | NR |
1997 | Braithwaite | Br J Surg | 43/93 46,2% (high dose 22/49 44,9%; low dose 21/44 47.7%) | NR | 7.5 | 3.2 | major: requiring surgery, transfusion | 9.7 | retroperitoneal bleeding, 3x myocardial infarction, general deteoriation, | NR | NR | NR | 2.2 | NR | NR | NR |
1997 | Payelle | Ann Vasc Surg | 90% immediate patency of 49 UK | 55% | 7 | 20 | major: requiring surgery, transfusion | 2.2 | myocardial infarction | NR | NR | NR | NR | NR | NR | NR |
1997 | Spence | AJR Am J Roentgenol | 73 | NR | 15 | NR | NR | 4 | afterguillotine, | NR | NR | NR | 8 | NR | NR | NR |
1997 | Matas | Ann Vasc Surg | 74,5 | 87,6 | 15 | 15 | minor: did not affect hospital stay nor required further treatment | 0 | NA | NR | NR | NR | 0 | NR | NR | NR |
1997 | Rickard | Cardiovasc Surg | native 71% 10/14 total; graft (prosth 79% 15/19 total, venous 75% 9/12 total) | NR | 16 | 22 | NR | 2 | NR | NR | NR | NR | 2 | NR | NR | NR |
1998 | Braithwaite | Br J Surg | 25/43 58% | NR | 23 | 9 | major: hemorrhage and systemic, minor: local complications | 44 | MOF, renal failure, bleeding gastric ulcer, stroke, pnuemonia, myocardial infarction,cardiac failure, pulmonayr embolism, septicimea | NR | NR | NR | 7 | NR | NR | NR |
1998 | Ouriel | N Engl J Med | 67,9% 167/246 (native 67/112 60%; bypass 100/134 75%) | NR | 12.5 | NR | NR | 1.6 | NR | NR | NR | NR | 19 | NR | NR | NR |
1998 | Wholey | Cathet Cardiovasc Diagn | 186/237 78,5% | NR | 6 | 11 | minor: did not require surgical intervention, resuscitation or delay in patient discharge | 1.3 | NR | NR | NR | NR | 5 | NR | NR | NR |
1999 | Lambert | Eur J Vasc Endovasc Surg | 44/102 43% | NR | 7.8 | 13.7 | mjar: requiring surgical intervention or blood transfusion | 2 | intracranial haemorrhage | NR | NR | NR | 19.6 | NR | NR | NR |
1999 | Suggs | Am J Surg | 76 | NR | 8.7 | 1.7 | Major: required transfusion or surgical intervention | 5.2 | myocardial infacrtion, ghemorrhagic stroke | NR | NR | NR | NR | 4 below knee, 5 above knee | NR | NR |
1999 | Ouriel | J Vasc Interv Radiol | 69.6% UK (49 total), 73.3% proUK (107/146 total) | NR | 10.5 | ? | NR | NR | NR | NR | NR | NR | 11 | NR | NR | NR |
1999 | Oguni | Radiat Med | 16/25 64% | 64 | 4 | 4 | NR | 24 | 1 intracranial haemorrhage, 1 embolic occlusions, 3 heart failure, 1 disseminated intravascular coagulation | NR | NR | NR | NR | NR | NR | NR |
2000 | Kröger | Angiology | 214/323 66% | NR | 3 | 6.5 | major: requiring blood transfusion | NR | NR | NR | NR | NR | NR | NR | NR | NR |
2000 | Schweizer | Angiology | NR | NR | 1.2 | 20 | NR | 0 | NA | NR | NR | NR | 9.5 | NR | NR | NR |
2001 | Swischuk | J Vasc Interv Radiol | 86% 64/74 (native 27/31 87,1 %; graft 37/43 86%) | 81 | 47 | 0 | All bleeding complications were major. | 1 | NR | NR | NR | NR | 6 | NR | NR | NR |
2001 | Korn | J Vasc Surg | 89 | 70 | 23 | 0 | major: significant hemorrhage | 4 | NR | NR | NR | NR | 9 | NR | NR | NR |
2001 | Haumer | Thromb Res | 94 | 87.5 | 15.6 | 25 | minor: local hematoma, macrohematuria, false aneurysm. major: major bleeding | 0 | Na | NR | NR | NR | 6.3 | NR | NR | NR |
2001 | Duda | Radiology | UK + Abciximab: 66, UK: 70; (native: 33/56 58,9%; bypass: 11/14 78,6%) | NR | 6 | 20 | Major complications were defined as procedure-related death, major bleeding: any intracranial, retroperitoneal, or intraocular hemorrhage or any clinical bleeding event associated with a hemoglobin level decrease of greater than 50 g/L—transfusion of blood components or whole blood or prolonged hospitalization | 0 | NA | NR | NR | NR | NR | NR | NR | NR |
2001 | Schwierz | Ann Vasc Surg | 72% 59/82 | NR | NR | NR | NR | NR | NR | NR | NR | NR | Nr | NR | NR | NR |
2001 | Mahler | J Endovasc Ther | 57% total 234 (rtPA 62% total 124; UK 50% n=110 | NR | 0.4 | 11.5 | major: cerebral hemorrhage, minor: gi-pain, local hematoma, infection puncture site | 0 | NA | NR | NR | NR | 6 | NR | NR | NR |
2002 | Castaneda | J Vasc Interv Radiol | 86/101 85% (1: 87, 2: 84, 3: 85) | NR | 15.2 | NR | Major bleeding was defined as any hemorrhage resulting in death, sur-gery, extended hospitalization, trans-fusion, a 5-g/dL decrease in hemoglo-bin level, or intracranial hemorrhage. Minor bleeding was defined as bleed-ing that did not have any major consequences | NR | NR | NR | NR | NR | 7 | NR | NR | NR |
2003 | Nehler | J Vasc Surg | 84/109 77,1% | NR | 13 | NR | requiring surgical intervention or transfusion | 2.7 | NR | NR | NR | NR | 6.7 | NR | NR | NR |
2003 | Holten | J Endovasc Ther | 27/32 84% | NR | 12.5 | NR | major: hematoma, sepsis, transient renal dysfunction, and a hemor-rhage at th | 0 | NA | NR | NR | NR | 9.4 | NR | NR | NR |
2003 | Conrad | J Vasc Surg | 49/69 71% (vein 33/48 68.8%; prosth 16/21 76.2%) | NR | NR | NR | bleeding: acces site and GI-bleed | 1.5 | congestive heart failure | NR | NR | NR | 25 | NR | NR | NR |
2003 | Tsetis | J Endovasc Ther | 28/34 82.4% | NR | 2.9 | 11.7 | major: fatal | 2.9 | NR | NR | NR | NR | 5.8 | NR | NR | NR |
2004 | Allie | J Endovasc Ther | 45/49 91,8% (TNK 23/25 92%; UK 22/24 91,7%) | 95.8 | 10.4 | 6.3 | majoe: requiring surgical intervention or tranfuaon | 0 | NA | NR | NR | NR | 4.2 | NR | NR | NR |
2004 | Breukinks | Ann Vasc Surg | 93/129 72% (native 67/87 77%; bypass 26/42 62%) | NR | 2 | 11 | major: requiting blood transfusion | 4 | NR | NR | NR | 30 | 11 | NR | 17 | NR |
2005 | Hanover | Ann Vasc Surg | 78/81 96.2% | NR | 4.9 | 12.3 | major: retroperitoneal hematoma, hematoma requiring transfusion, sustained renal failure, or death. | 2.4 | NR | 9.3 | NR | NR | 19.6 | NR | 23.3 | 30 |
2006 | Plate | Eur J Vasc Endovasc Surg | 86/119 72.3% (1: 45/58 78% 2: 41/61 67%) | 63 | 11.5 | 16 | major: requiting surgical intervetion or tranfusion | 10.7 | NR | NR | 21.5 | NR | 7 | NR | NR | 12.4 |
2006 | Tepe | Radiology | 34/50% 68% (rtPA); UK data (n=30) merged with earlier published data | NR | NR | NR | major: requiring transfusion | 0 | NA | NR | 92 | 90 | NR | NR | NR | 4 |
2007 | Wissgot | J Endovasc Ther | 22/25 88% | 88 | 0 | 4 | NR | 0 | NA | NR | NR | 0 | 0 | NR | NR | 0 |
2007 | Geier | Vasa | 67/82 82% | NR | 7.3 | 11 | major: need for ttransfusiom or interuruption of thrpombolytic treatment or prolonged hospital stay | 1 | NR | NR | 8.5 | NR | 1 | NR | NR | 2 |
2008 | Disini | Clin Radiol | 25/39 64% (native 19/30 63.3%; bypass 6/9 66.7%) | NR | 7.5 | 15.5 | major: cses with sever systemic or intracranial bleeding, with or withiut requirement for blood transfusion | 5.1 | NR | NR | 7.7 | NR | NR | NR | NR | 20.5 |
2010 | Han | J Vasc Surg | HA004 69/149 56.3%; HA007 18/51 35.3% | NR | 8 | NR | NR | 3.5 | NR | NR | NR | NR | 20.8 | NR | NR | NR |
2011 | Kuoppala | J Thromb Thrombolysis | 170/218 78% | NR | 18 | 33 | major: when thrombolysis had to be discontinued | 5 | cerebral hemorrhage and limb ischemia | NR | NR | NR | 11 | NR | NR | NR |
2011 | Kashyap | J Vasc Surg | 106/129 82% | NR | 12 | 11 | major: requiring transfusion or surgical intervention | 6 | NR | NR | 14.3 | NR | 15.5 | NR | NR | NR |
2011 | Lokse | Eur J Vasc Endovasc Surg | 85.4% 181/212 | NR | 4 | NR | NR | NR | NR | NR | 40 | NR | NR | NR | NR | 19 |
2011 | Kuhn | AJR Am J Roentgenol | 95/129 73.6% (native 58/77 75.3%; bypass 37/52 71.1%) | NR | 10.9 | 20.2 | major: extensive bleeding or death | 2.3 | NR | NR | NR | NR | 1.1 | NR | NR | 10.6 |
2012 | Schrijver | Cardiovasc Intervent Radiol | 20/21 95% | NR | 5 | 0 | minor: no consequence, no therapy, nominal therapy (including overnight admission), major: requiring minor, major therapy, death, permanent advers sequelae | 0 | NA | NR | NR | NR | 0 | NR | NR | NR |
2011 | Koraen | J Vasc Surg | 105/123 85% | NR | 13.2 | NR | major: hemorrhage of such severity thata intervention or termination of trombolysis was required | 6.5 | NR | NR | 13 | NR | 11 | NR | NR | 25.4 |
2011 | Limtungturakul | J Med Assoc Thai | 53/63 84.1 | 71.24 | 6 | 6 | major:hemorrhagic stroke, retroperitoneal bleeding | 28.6 | intracranial bleeding, malignancy, sepsis, myocardial infarction | NR | NR | NR | 7.6 | NR | NR | NR |
2011 | Schrijver | J Cardiovasc Surg (Torino) | 51/62 82% | 82 | 3 | 2 | major: requiring surgical intervention, blood transfusion | 2 | progressive ischemia | NR | 5 | NR | 8 | NR | 4 | NR |
2012 | Chen | Chin Med J (Engl) | 36/44 81.2% (native 26/32 81.2%; bypass 9/11 81.8%) | 81.2 | 0 | NR | NR | 0 | NA | NR | 0 | NR | 4.5 | NR | NR | NR |
2012 | Marder | J Thromb Haemost | 38/62 61% | NR | 4.8 | 16.9 | major:intracranial hemorrhag or non cerebral bleeding requiring bllod transfusion or that caused hemodynamic compromise. minor:other than major | 2.4 | ‘not related to plasmin’ | NR | NR | NR | 2.4 | NR | NR | NR |
2013 | Yuan | Thorac Cardiovasc Surg | 102/103 99% | 99 | 3 | 6 | NR | 0 | NA | NR | NR | NR | NR | NR | NR | NR |
2013 | Falkowski | Eur J Vasc Endovasc Surg | 83/97 85,6 (native 39/45 86.7%; bypass 41/52 78.8%) | 88.7 | 10.3 | NR | major: death, lif-threathening conditions, conditions resulting in potential disability, need for prolonged hospitalisation and/or requiring additional procedure | 2.1 | intracranial hemorrhage, post-operative complications (non specified) | NR | 15 | 29 | 4.1 | NR | NR | 17.5 |
2013 | Skeik | Vasc Endovascular Surg | 86,3 total 51 arterial occlusions | 86,3 | 14.5 | NR | major:death, intracranial hemorrhage, symptomatic bleeds into a critical area or organ. requiring transfusion | 1.4 | NR | NR | NR | NR | 2.8 | NR | NR | NR |
2013 | Wongwanit | J Med Assoc Thai | 28/37 75.7 | 86.5 | 17.9 | 18.9 | maor: unexpected surgical procedure, > 4 units of blood, major stroke and death | 10.8 | NR | NR | NR | NR | 13.5 | NR | 21.6 | 21.6 |
2014 | Vakhitov | Ann Vasc Surg | 115/149 77.2% | NR | 1.3 | NR | major: requiting termination of thrombolysis or surgery | 2.7 | septicemia, myocardial infarction, massive thromboembolism | NR | NR | NR | 8.7 | NR | NR | NR |
2013 | Hundt | Eur.J.Radiol. | NR | NR | 7 | 8.5 | major: systemic bleeding, distal embolus | 0 | NA | NR | NR | NR | NR | NR | NR | 0 |
2014 | Grip | Br J Surg | NR | NR | – | – | major: requiring cessation or transfusion | 7.4 | NR | NR | NR | NR | 6.6 | NR | NR | NR |
2015 | Taha | J Vasc Surg | 550/673 81.7% (native 310/393 78.0%; bypass 241/280 86.1%) | NR | 38.5 | – | NR | 4.4 | NR | NR | NR | NR | 13 | NR | NR | NR |
2014 | Ebben | Eur J Vasc Endovasc Surg | 124/154 81% (native 24/26 92,31%; bypass prosth 21/24 87,5%; bypass vein 16/26 61,54%) | NR | 5.8 | NR | NR | 5.4 | NR | NR | 12.9 | 18.7 | 6.5 | NR | NR | 13.0 |
2015 | Lurie | J Vasc Surg | 120/171 70%; low dose 87/129 67%, high dose: 33/42 79% (native 60/86 70%; bypass 60/85 71% (prosth 49/64 77%; venous 10/19 53%)) | NR | 5 | 12 | NR | 6 | NR | NR | NR | NR | NR | NR | low 19, high 12 | NR |
2015 | Schrijver | J Endovasc Ther | 33/84 39,3% | NR | 3.6 | NR | NR | 6 | NR | NR | NR | NR | 5.9 | NR | NR | NR |
2015 | Schrijver | Ann Vasc Surg | 27/32 84% ST, 21/28 75% UST (native bypass) | NR | 12 | 2 | major: hemorrhage cessaitating discontinuation of thrombolysis, transfusion or surgical intervention | 3.3 | cardiac failure, intracranial bleeding | NR | NR | NR | 6.7 | NR | NR | NR |
native 69% /89, bypass 69% /70, total 159 69% | NR | 12 | NR | 3.8 | 2 intracranial bleeding, 1 myocardial infarction, 1 sepsis, 1 peripheral ischemia, 1 bowel ischemia | NR | NR | NR | 11.3 | NR | 23 | NR |